Source: Pharmaceutical Technology
Basilea may receive additional funding from CARB-X for further preclinical and early clinical development, contingent on certain undisclosed project milestones, as per the company. Image Credit: Marian Weyo / Shutterstock. Source: Pharmaceutical Technology
Switzerland-based Basilea Pharmaceutica has received a $0.9m grant from the global non-profit, Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), to develop a new antibiotic. Free WhitepaperPepSetsTM and their Applications
Peptide libraries are a powerful tool in biological research for screening large numbers of peptides in the search for the few, critical bioactive peptides.
Mimotopes PepSets are custom-synthesized peptide libraries supplied unpuried for fast, efcient screening work. These sets of chemically synthesized individual peptides are made
on a small scale using Mimotopes’ unique proprietary parallel array synthesis platform. PepSets comprising hundreds, or even thousands of peptides, are rapidly synthesized and shipped within a few weeks of ordering. Source: Pharmaceutical Technology
Antigua & Barbuda (+1268)
Bosnia Herzegovina (+387)
Cape Verde Islands (+238)
Central African Republic (+236)
Dominican Republic (+1809)
Sao Tome & Principe (+239)
Trinidad & Tobago (+1868)
Turks & Caicos Islands (+1649)
United Arab Emirates (+971)
Virgin Islands - British (+1284)
Virgin Islands - US (+1340)
Bonaire, Sint Eustatius and Saba
British Indian Ocean Territory
French Southern Territories
Heard Island and McDonald Islands
Saint Helena, Ascension and Tristan da Cunha
Saint Pierre and Miquelon
Saint Vincent and The Grenadines
South Georgia and The South
US Minor Outlying Islands
By downloading this case study, you acknowledge that GlobalData may share your information with Mimotopes Thematic and that your personal data will be used as described in their Privacy Policy Submit
Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Thank you.You will receive an email shortly. Please check for download the Whitepaper.
Go deeper with GlobalData
Source: Pharmaceutical Technology
Source: Pharmaceutical Technology
The gold standard of business intelligence.
The grant will fund the preclinical development of an antibiotic candidate until the candidate’s nomination, which is expected in H2 this year.
Basilea added that the company may receive additional funding from CARB-X for further preclinical and early clinical development, contingent on certain undisclosed project milestones. The antibiotic programme that received funding was developed using the Spexis’ outer membrane protein targeting antibiotics (OMPTA) technology, which Basilea acquired in January. The OMPTA class of antibiotics binds dually to lipopolysaccharide and outer-membrane proteins. These proteins provide structural integrity and a permeability barrier to protect the gram-negative bacterial cell. Therefore, any disruption in the function of these proteins can cause the bacteria to die.
Prothea debuts with $13m to develop cancer diagnostics and treatment Source: Pharmaceutical Technology
Source: Pharmaceutical Technology
Basilea has previously received funds from the US Government to develop its portfolio of antibacterials and antifungals. The company’s recently approved antibiotic Zevtera (ceftobiprole) was developed through subsidised funding from BARDA. Antimicrobial resistance (AMR) has become a growing issue in recent years, with the World Health Organisation (WHO) declaring it one of the top global public health and development threats. The US bacterial infection market is expected to be worth $4.1bn by 2024, according to GlobalData. Another antibiotic currently in development is Roche’s zosurabalpin. It is classified under a new antibiotic class of drugs called tethered macrocyclic peptides. Zosurabalpin targets the lipopolysaccharide (LPS) transport systems, which is important for maintaining bacterial cell structure among other functions. Early R&D project coverage on Pharmaceutical Technology is supported by Mimotopes.
Editorial content is independently produced and follows highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperPepSetsTM and their Applications
Peptide libraries are a powerful tool in biological research for screening large numbers of peptides in the search for the few, critical bioactive peptides.
Mimotopes PepSets are custom-synthesized peptide libraries supplied unpuried for fast, efcient screening work. These sets of chemically synthesized individual peptides are made
on a small scale using Mimotopes’ unique proprietary parallel array synthesis platform. PepSets comprising hundreds, or even thousands of peptides, are rapidly synthesized and shipped within a few weeks of ordering. Source: Pharmaceutical Technology
Antigua & Barbuda (+1268)
Bosnia Herzegovina (+387)
Cape Verde Islands (+238)
Central African Republic (+236)
Dominican Republic (+1809)
Sao Tome & Principe (+239)
Trinidad & Tobago (+1868)
Turks & Caicos Islands (+1649)
United Arab Emirates (+971)
Virgin Islands - British (+1284)
Virgin Islands - US (+1340)
Bonaire, Sint Eustatius and Saba
British Indian Ocean Territory
French Southern Territories
Heard Island and McDonald Islands
Saint Helena, Ascension and Tristan da Cunha
Saint Pierre and Miquelon
Saint Vincent and The Grenadines
South Georgia and The South
US Minor Outlying Islands
By downloading this case study, you acknowledge that GlobalData may share your information with Mimotopes Thematic and that your personal data will be used as described in their Privacy Policy Submit
Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Thank you.You will receive an email shortly. Please check for download the Whitepaper.